title: Tositumomab and iodine I 131 tositumomab (Bexaar).
abstract: Tositumomab and iodine I 131 tositumomab (Bexaar) therapeutic regimen targets monoclonal antibodies against the CD20 antigen expressed in non-Hodgkin lymphoma. This article reviews the mechanism of action and clinical indications for this regimen.
authors: Department of Radiology, Division of Neuroradiology, University of Michigan Health System, Ann Arbor, Michigan 48109, USA. ashoks@med.umich.edu
authors: A
authors: A
authors: Srinivasan
authors: S K
authors: SK
authors: Mukherji
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000532:radiotherapy*; D016499:Radioimmunotherapy; D014057:Tomography, X-Ray Computed
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; C119496:tositumomab I-131